Genetic Testing in Dyslipidemia: A Scientific Statement From the National Lipid Association
Affiliations
- PMID: 32507592
- DOI: 10.1016/j.jacl.2020.04.011
Abstract
The genetic basis for more than 2 dozen monogenic dyslipidemias has largely been defined. Genetic technologies, such as DNA sequencing, can detect both rare and common DNA variants underlying dyslipidemias, and these methods are increasingly available. Although patients with extreme abnormalities in low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol may be considered for genetic testing, it is only in a minority of patients that the results will alter treatment or outcomes. Currently, there is potential clinical utility of genetic testing for familial hypercholesterolemia, familial chylomicronemia syndrome, sitosterolemia, lysosomal acid lipase deficiency, and a few other rare disorders, and this will increase the demand for reliable genetic diagnostic methods at lower cost. Clinical indications for genetic testing for most dyslipidemias are not clearly established and currently no guidelines exist. A shared decision-making model between the patient and the provider is essential as patient values and preferences play a very strong role. Potential benefits of genetic testing include providing a firm diagnosis in many cases, guiding optimal management and prevention strategies, advancing care strategies beyond currently available treatments, and contributing to overall scientific progress. Understanding the limitations and risks of genetic testing techniques is also important, as is careful interpretation of genetic test results to achieve the greatest benefit. Here we review laboratory methods, as well as technical, biological, clinical, and ethical implications and applications of genetic testing in dyslipidemias.
Keywords: DNA sequencing; Genetic counseling; Hyperlipidemia; Hypolipidemia; Monogenic; Polygenic.
Copyright © 2020 National Lipid Association. Published by Elsevier Inc. All rights reserved.
Similar articles
- Screening for Lipid Disorders in Children and Adolescents [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Jul. Report No.: 07-0598-EF-1.PMID: 20722144 Free Books & Documents. Review.
- The role of genetic testing in dyslipidaemia.Pathology. 2019 Feb;51(2):184-192. doi: 10.1016/j.pathol.2018.10.014. Epub 2018 Dec 14.PMID: 30558903 Review.
- Update on the molecular biology of dyslipidemias.Clin Chim Acta. 2016 Feb 15;454:143-85. doi: 10.1016/j.cca.2015.10.033. Epub 2015 Nov 4.PMID: 26546829 Review.
- Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug. Report No.: 14-05204-EF-1.PMID: 27559550 Free Books & Documents. Review.
- Targeted next-generation sequencing in monogenic dyslipidemias.Curr Opin Lipidol. 2015 Apr;26(2):103-13. doi: 10.1097/MOL.0000000000000163.PMID: 25692347 Review.
No hay comentarios:
Publicar un comentario